D. Pol, Dictionnaire encyclopédique des drogues. Paris: Ellipses, p.256, 2002.

J. J. Moreau, Du hachisch et de l'aliénation mentale: études psychologiques

M. Tabary, Consommation de cannabis en Nouvelle Calédonie : état des lieux en, p.175, 2008.

D. Richard, J. Senon, and . Le, Paris: Presses universitaires de France, p.128, 2010.

B. Jean, Pharmacognosie, phytochimie, plantes médicinales, p.1268, 2009.

C. Botanique,

, UFCM, Disponible sur, p.12, 2015.

S. Filatriau, Cigarette électronique, cannabis et THC : usage thérapeutique et récréatif

J. Lbsjs81b-le-cannabis and . Le-dépénaliser-ou-le-légaliser, est-ce un crime ?

M. Didier and . Lambert, Les vertus thérapeutiques du cannabis à travers les millénaires, Journal de Pharmacie de Belgique, vol.57, p.22, 2002.

K. Hostettmann, Les plantes qui deviennent des drogues, Lausanne: Favre, p.135, 2002.

M. Botineau, Botanique systématique et appliquée des plantes à fleur, Tec & Doc, p.1335, 2010.

A. A. Izzo, F. Borrelli, R. Capasso, D. Marzo, V. Mechoulam et al., Les Phyto-cannabinoïdes Non-psychotres: Les nouvelles Opportunités d'une plante, p.16, 2016.

;. Disponible-sur, C. Thc, C. , C. , T. et al.,

, Montana BioTech, 2013.

. Disponible,

, Cauchon veut décriminaliser la marijuana d'ici, 2003.

L. Devoir,

. Disponible,

, Arrêté à la gare de Rouen avec 1,2 kg de résine de cannabis dans son sac à dos

. Disponible,

D. Richard, Le cannabis et sa consommation, p.128, 2009.

. Greenweez, com-Magasin bio en ligne | Produits écologiques et Produits bio moins cher

D. Richard, R. Mechoulam, M. Guzman, L. Ph, . Michka et al., Cannabis médical: du chanvre indien aux cannabinoïdes de synthèse, Mama éditions

V. Seutin, J. Scuvée-moreau, and E. Quertemont, Regards croisés sur le cannabis, Editions Mardaga, p.289, 2010.

T. Flowers, Marijuana Herbal Cookbook, p.100, 1995.

, Vaporisateur de Cannabis-Tests & Conseils

J. Senon, M. Valleur, and D. Richard, Dictionnaire des drogues et des dépendances, Paris: Larousse, p.751, 2009.

F. Beck, S. Legleye, and S. Spilka, L'usage de cannabis chez les adolescents et les jeunes adultes : comparaison des consommations européennes, Santé Publique. 22 janv, 2008.

. Produits, , p.12, 2015.

G. Dupuy, F. Vorspan, and J. Lépine, Épidémiologie des usages de substances addictives : résultats d'études réalisées en France et perspectives internationales. Annales Médicopsychologiques, revue psychiatrique, sept, vol.167, issue.7, pp.498-503, 2009.

E. Ducongé and H. Chabrol, Relations entre les expériences dissociatives et la consommation de cannabis chez l'adolescent et le jeune adulte, Adolescence. avr, vol.53, issue.3, pp.128-131, 2005.

F. Beck, S. Legleye, and S. Spilka, Consommation et surconsommation de cannabis : apports et limites de l'épidémiologie, Psychotropes. 1 avr, vol.13, issue.1, pp.9-31, 2007.

M. A. Huestis, A. H. Sampson, B. J. Holicky, J. E. Henningfield, and E. J. Cone, Characterization of the absorption phase of marijuana smoking, Clin Pharmacol Ther, vol.52, issue.1, pp.31-41, 1992.

J. Goullé, E. Saussereau, and C. Lacroix, Pharmacocinétique du delta-9tétrahydrocannabinol (THC), Annales Pharmaceutiques Françaises. août, vol.66, issue.4, pp.232-276, 2008.

E. R. Garrett, Pharmacokinetics and disposition of delta 9-tetrahydrocannabinol and its metabolites, Adv Biosci. déc, vol.22, issue.23, pp.105-126, 1977.

D. Lee, R. Vandrey, G. Milman, M. Bergamaschi, D. R. Mendu et al., Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration, Anal Bioanal Chem. 6 juill, vol.405, issue.23, pp.7269-79, 2013.

C. H. Ashton, Pharmacology and effects of cannabis: a brief review, The British Journal of Psychiatry. 1 févr, vol.178, issue.2, pp.101-107, 2001.

, Cannabinoïdes de synthèse : aspects pharmacologiques

. Disponible,

, Cannabis: quels effets sur le comportement et la santé? Paris: INSERM, vol.34, p.428, 2001.

L. A. Matsuda, S. J. Lolait, M. J. Brownstein, A. C. Young, and T. I. Bonner, Structure of a cannabinoid receptor and functional expression of the cloned cDNA, Nature, vol.346, issue.6284, pp.561-565, 1990.

G. Moldrich and T. Wenger, Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides, vol.21, pp.1735-1777, 2000.

M. Bouaboula and P. Casellas, Récepteurs cannabinoïdes, Doul et analg. déc, vol.14, issue.4, pp.207-218, 2001.

, What Is-and What Causes-the Marijuana « High »?-Medical MarijuanaProCon.org, 2015.

. Disponible,

S. Munro, K. L. Thomas, and M. Abu-shaar, Molecular characterization of a peripheral receptor for cannabinoids, 1993.

. Disponible,

, The mechanism of action of cannabis, p.12, 2015.

. Disponible,

D. Marzo, V. Melck, D. Bisogno, T. , D. Petrocellis et al., Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action, Trends in Neurosciences. 1 déc, vol.21, issue.12, pp.521-529, 1998.

S. Lauwagie, E. Stern, R. Millet, and P. Depreux, Cannabinoïdes et pharmacologie des récepteurs aux cannabinoïdes, La Lettre du pharmacologue, vol.20, issue.3, pp.68-78, 2006.

M. Guzmán, I. Galve-roperh, and C. Sánchez, Ceramide: a new second messenger of cannabinoid action, Trends in Pharmacological Sciences. 1 janv, vol.22, issue.1, pp.19-22, 2001.

A. Tóth, J. Boczán, N. Kedei, E. Lizanecz, Z. Bagi et al., Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain, Molecular Brain Research. 27 avr, vol.135, issue.1-2, pp.162-170, 2005.

C. Gouvernement and . Sc, Renseignements destinés aux professionnels de la santé : Le cannabis (marijuana, marihuana) et les cannabinoïdes [Santé Canada, 2013.

J. Guindon and A. G. Hohmann, The Endocannabinoid System and Pain, CNS Neurol Disord Drug Targets. déc, vol.8, issue.6, pp.403-424, 2009.

P. Beaulieu, Pharmacologie de la douleur, p.608, 2005.

W. A. Devane, L. Hanus, A. Breuer, R. G. Pertwee, L. A. Stevenson et al., Isolation and structure of a brain constituent that binds to the cannabinoid receptor, Science, vol.258, issue.5090, pp.1946-1955, 1992.

T. Sugiura, S. Kondo, A. Sukagawa, T. Tonegawa, S. Nakane et al.,

, Enzymatic Synthesis of Anandamide, an Endogenous Cannabinoid Receptor Ligand, through N-Acylphosphatidylethanolamine Pathway in Testis: Involvement of Ca2+Dependent Transacylase and Phosphodiesterase Activities, Biochemical and Biophysical Research Communications. 5 janv, vol.218, issue.1, pp.113-120, 1996.

R. Mechoulam, E. Fride, S. Ben-shabat, U. Meiri, and M. Horowitz, Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid, European Journal of Pharmacology, vol.362, issue.1, pp.1-3, 1998.

F. Grotenhermen, Cannabis en médecine: un guide pratique des applications médicales du cannabis et du THC, Editions Indica, p.217, 2009.

T. Maejima, T. Ohno-shosaku, and M. Kano, Endogenous cannabinoid as a retrograde messenger from depolarized postsynaptic neurons to presynaptic terminals
DOI : 10.1016/s0168-0102(01)00241-3

, Neuroscience Research. 1 juill, vol.40, issue.3, pp.205-215, 2001.

A. Scheen, V. Seutin, V. Gaal, and F. L. Le-système-endocannabinoïde-dans-le-cerveau, , vol.63, pp.5-6, 2008.

. Disponible,

J. Desroches and P. Beaulieu, Système cannabinoïde et douleur: quelle place en thérapeutique? Douleur, vol.162, pp.1505-1518, 2008.

P. Pacher, S. Batkai, and G. Kunos, The endocannabioid system as an emerging target of pharmacotherapy, Pharmacol Rev, vol.58, pp.389-462, 2006.

D. Dion, Science des cannabinoïdes 101 : le cannabidiol

S. Seeds and F. Blog,

, Nouveaux produits de synthèse-Synthèse des connaissances-OFDT

A. J. Scheen, V. Gaal, and L. F. , « Effets cardio-métaboliques du rimonabant chez le sujet obèse ou en surpoids avec dyslipidémie ou diabète de type 2 », Rev Med Liège, vol.62, pp.81-85, 2007.

N. Donzé and M. Augsburger, Cannabis, haschich & Cie: un enjeu pour l'individu, la famille et la société, Editions Saint-Augustin, p.148, 2008.

N. Saghafi, D. K. Lam, and B. L. Schmidt, Cannabinoids attenuate cancer pain and proliferation in a mouse model, Neuroscience letters, vol.488, issue.3, pp.247-51, 2011.

S. Oesch, D. Walter, M. Wachtel, K. Pretre, M. Salazar et al., Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma, Molecular cancer therapeutics, vol.8, issue.7, pp.1838-1883, 2009.

L. Karila and M. Reynaud,

, Ann Med Interne (Paris). juin, vol.154, issue.1, pp.58-64, 2003.

P. Bech, L. Rafaelsen, and O. J. Rafaelsen, Cannabis and alcohol: Effects on estimation of time and distance, Psychopharmacologia. déc, vol.32, issue.4, pp.373-81, 1973.

I. Kurzthaler, M. Hummer, C. Miller, B. Sperner-unterweger, V. Günther et al., Effect of cannabis use on cognitive functions and driving ability, Journal of Clinical Psychiatry, vol.60, issue.6, pp.395-404, 1999.

J. Costentin, Le cannabis-données neurobiologiques récentes éclairant les perturbations de la conduite des véhicules, Annales Pharmaceutiques Françaises. mai, vol.64, issue.3, pp.148-59, 2006.

B. Laumon, Cannabis intoxication and fatal road crashes in France: population based case-control study, BMJ. 10 déc, vol.331, issue.7529, pp.1371-1371, 2005.

B. Park, J. M. Mcpartland, and M. Glass, Cannabis, cannabinoids and reproduction

, Prostaglandins, Leukotrienes and Essential Fatty Acids. févr, vol.70, issue.2, pp.189-97, 2004.

D. Richard and J. Senon, Activité pharmacologique du cannabis. Que sais-je ?, pp.45-101, 2010.

F. Smit, L. Bolier, and P. Cuijpers, Cannabis use as a probable causative factor in the later development of schizophrenia, Ned Tijdschr Geneeskd, vol.147, pp.2178-83, 2003.

A. Dervaux, X. Laqueille, M. C. Bourdel, M. H. Leborgne, J. P. Olie et al., Cannabis and schizophrenia : demographic and clinical correlates, Encéphale, vol.29, pp.11-18, 2003.

E. M. Tunbridge, P. J. Harrison, and D. R. Weinberger, Catechol-O-Methyltransferase, Cognition, and Psychosis: Val158Met and Beyond, Biological Psychiatry. 15 juill, vol.60, issue.2, pp.141-51, 2006.

A. Caspi, T. E. Moffitt, M. Cannon, J. Mcclay, R. Murray et al., Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction, Biological psychiatry, vol.57, issue.10, pp.1117-1144, 2005.

R. Van-winkel, N. J. Van-beveren, C. Simons, R. S. Kahn, D. H. Linszen et al., AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder, Neuropsychopharmacology, vol.36, issue.12, pp.2529-2566, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00661556

R. Nordmann and F. Académie-nationale-de-médecine, Académie (Paris), éditeurs. Désamorcer le cannabis dès l'école. Cachan: Éd. médicales internationales, p.pp, 2006.

. Disponible,

N. Marie and F. Noble, Dépendance aux drogues : avancées de la neurobiologie et perspectives thérapeutiques, La Presse Médicale. déc, vol.41, issue.12, pp.1259-70, 2012.

J. Costentin and . Dopamine, amine du plaisir, pp.97-116, 1999.

K. Tsou, S. L. Patrick, and J. M. Walker, Physical withdrawal in rats tolerant to ? 9tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist, European Journal of Pharmacology, vol.280, issue.3, pp.13-18, 1995.

M. Kouznetsova, B. Kelley, M. Shen, and S. A. Thayer, Desensitization of cannabinoidmediated presynaptic inhibition of neurotransmission between rat hippocampal neurons in culture, Molecular pharmacology, vol.61, issue.3, pp.477-85, 2002.

T. Rubino, D. Viganò, P. Massi, and D. Parolaro, Changes in the Cannabinoid Receptor Binding, G Protein Coupling, and Cyclic AMP Cascade in the CNS of Rats Tolerant to and Dependent on the Synthetic Cannabinoid Compound CP55,940, Journal of Neurochemistry, vol.75, issue.5, pp.2080-2086, 2000.

A. Oviedo, J. Glowa, and M. Herkenham, Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study, Brain Research. 9 juill, vol.616, issue.1-2, pp.293-302, 1993.

R. T. Jones, N. Benowitz, and J. Bachman, Clinical studies of cannabis tolerance and dependence, Annals of the New York Academy of Sciences, vol.282, issue.1, pp.221-260, 1976.

A. Georgotas and P. Zeidenberg, Observations on the effects of four weeks of heavy marihuana smoking on group interaction and individual behavior, Comprehensive Psychiatry, vol.20, issue.5, pp.427-459, 1979.

M. Haney, A. S. Ward, S. D. Comer, R. W. Foltin, and M. W. Fischman, Abstinence symptoms following smoked marijuana in humans, Psychopharmacology, vol.141, issue.4, pp.395-404, 1999.

R. Prescrire, Cannabis et grossesse: syndromes de sevrage à la naissance et doutes sur des effets à long terme. La revue Prescrire, vol.31, pp.509-513, 2011.

S. Lamy, X. Laqueille, and F. Thibaut, Conséquences potentielles de la consommation de tabac, de cannabis et de cocaïne par la femme enceinte sur la grossesse, 2014.

. Disponible,

A. Peter and F. Phd, The Consequences of Marijuana Use During Pregnancy: A Review of the Human Literature, Journal of Cannabis Therapeutics. 1 juin, vol.2, issue.3-4, pp.85-104, 2002.

P. A. Fried and A. M. Smith, A literature review of the consequences of prenatal marihuana exposure: an emerging theme of a deficiency in aspects of executive function, Neurotoxicology and teratology, vol.23, issue.1, pp.1-11, 2001.

L. Goldschmidt, N. L. Day, and G. A. Richardson, Effects of prenatal marijuana exposure on child behavior problems at age 10, Neurotoxicology and teratology, vol.22, issue.3, pp.325-361, 2000.

C. Davitian, M. Uzan, A. Tigaizin, G. Ducarme, H. Dauphin et al., Consommation maternelle de cannabis et retard de croissance intra-utérin, Gynécologie obstétrique & fertilité, vol.34, issue.7, pp.632-639, 2006.

, Bedrocan medicinale cannabis | home, 2015.

. Disponible,

A. Hazekamp, Une évaluation de la qualité du cannabis à usage thérapeutique aux PaysBas, 2016.

. Disponible,

S. Wright, P. Duncombe, and D. G. Altman, Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach, Trials, vol.13, issue.1, p.189, 2012.

B. Chakravarti, J. Ravi, and R. K. Ganju, Cannabinoids as therapeutic agents in cancer: current status and future implications, Oncotarget, vol.5, issue.15, p.5852, 2014.

I. Brown, M. G. Cascio, D. Rotondo, R. G. Pertwee, S. D. Heys et al., Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators, Progress in Lipid Research. janv, vol.52, issue.1, pp.80-109, 2013.

S. Pisanti and M. Bifulco, Endocannabinoid system modulation in cancer biology and therapy, Pharmacological Research. août, vol.60, issue.2, pp.107-123, 2009.

A. Châtel, Voies de signalisation des MAP kinases et apoptose chez l'éponge Suberites domuncula et la moule Mytilus galloprovincialis, 2009.

A. Ligresti, T. Bisogno, I. Matias, D. Petrocellis, L. Cascio et al., Possible endocannabinoid control of colorectal cancer growth, Gastroenterology. sept, vol.125, issue.3, pp.677-87, 2003.

, Hypothesis: cannabinoid therapy for the treatment of gliomas?

. Disponible,

, Cannabinoides: substances potentiellement antitumoraales?, p.101

. Disponible,

M. Guzmán, M. J. Duarte, C. Blázquez, J. Ravina, M. C. Rosa et al., A pilot clinical study of ?9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme, Br J Cancer. 27 juin, vol.95, issue.2, pp.197-203, 2006.

G. Velasco, I. Galve-roperh, C. Sánchez, C. Blázquez, A. Haro et al., Cannabinoids and ceramide: Two lipids acting hand-by-hand, Life Sciences. 19 août, vol.77, issue.14, pp.1723-1754, 2005.

M. M. Caffarel, C. Andradas, E. Pérez-gómez, M. Guzmán, and C. Sánchez, Cannabinoids: A new hope for breast cancer therapy? Cancer Treatment Reviews, vol.38, pp.911-919, 2012.

N. Leleu-chavain, C. Biot, P. Chavatte, and R. Millet, Du cannabis aux agonistes sélectifs du récepteur CB2-Des molécules aux nombreuses vertus thérapeutiques. médecine/sciences, vol.29, p.6, 2013.

M. M. Caffarel, D. Sarrió, J. Palacios, M. Guzmán, and C. Sánchez, ?9-Tetrahydrocannabinol Inhibits Cell Cycle Progression in Human Breast Cancer Cells through Cdc2 Regulation, Cancer Res. 1 juill, vol.66, issue.13, pp.6615-6636, 2006.

S. Vignot, B. Besse, M. Rouge-t-de-la, C. Massard, J. Spano et al., Cannabis et cancer. Bulletin du Cancer. 31 janv, vol.93, issue.2, pp.163-70, 2006.

B. Amar and M. , Cannabinoids in medicine: A review of their therapeutic potential, Journal of Ethnopharmacology. 21 avr, vol.105, issue.1-2, pp.1-25, 2006.

R. Noyes, S. F. Brunk, D. A. Baram, and A. Canter, Analgesic Effect of Delta-9Tetrahydrocannabinol, The Journal of Clinical Pharmacology. 3 févr, vol.15, issue.23, pp.139-182, 1975.

J. R. Johnson, M. Burnell-nugent, D. Lossignol, E. D. Ganae-motan, R. Potts et al.,

. Multicenter and R. Double-blind, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain, Journal of Pain and Symptom Management. févr, vol.39, issue.2, pp.167-79, 2010.

B. Calvino, Cannabinoïdes et douleur. Douleurs : Evaluation-Diagnostic-Traitement, vol.8, pp.218-244, 2007.

M. Karst, K. Salim, S. Burstein, C. I. Hoy, L. Schneider et al., Analgesic effect of the synthetic cannabinoid ct-3 on chronic neuropathic pain: A randomized controlled trial, JAMA, vol.290, issue.13, pp.1757-62, 2003.

J. Manzanares, J. Corchero, J. Romero, J. J. Fernández-ruiz, J. A. Ramos et al., Pharmacological and biochemical interactions between opioids and cannabinoids, Trends in Pharmacological Sciences. 1 juill, vol.20, issue.7, pp.287-94, 1999.

B. C. De-jong, P. D. Mcfarland, W. Machekano, R. Israelski, and D. M. , Marijuana use and its association with adherence to antiretroviral therapy among HIV-infected persons with moderate to severe nausea, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.38, issue.1, pp.43-49, 2005.

E. M. Williamson and F. J. Evans, Cannabinoids in clinical practice, Drugs, vol.60, issue.6, pp.1303-1317, 2000.

M. Cannabis and . De-parkinson,

U. , , 2015.

. Disponible,

K. A. Sieradzan, S. H. Fox, M. Hill, J. Dick, A. R. Crossman et al., Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: A pilot study, Neurology. 11 déc, vol.57, issue.11, pp.2108-2119, 2001.

C. Le, diminuer par deux le nombre de crises chez plus de la moitié des enfants épileptiques

C. Thérapeutique, Disponible sur

. Cannabis, . Spasticité, . Sclérose-en-plaques, and . Paraplégie,

R. G. Pertwee, Cannabinoids and multiple sclerosis, Pharmacology & Therapeutics. août, vol.95, issue.2, pp.165-74, 2002.

P. Consroe, R. Musty, J. Rein, W. Tillery, and R. Pertwee, The perceived effects of smoked cannabis on patients with multiple sclerosis, European neurology, vol.38, issue.1, pp.44-52, 1997.

L. M. Eubanks, C. J. Rogers, . Beuscher, G. F. Koob, A. J. Olson et al., A Molecular Link between the Active Component of Marijuana and Alzheimer's Disease Pathology, Molecular Pharmaceutics. 1 déc, vol.3, issue.6, pp.773-780, 2006.

, Les 5 principaux avantages du cannabis pour le traitement de la maladie d'Alzheimer

S. Seeds and F. Blog,

A. C. Campos, F. A. Moreira, F. V. Gomes, E. Bel, and F. S. Guimarães, Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders, Phil Trans R Soc B. 5 déc, vol.367, pp.3364-78, 1607.

S. Pinar-sueiro, R. Rodríguez-puertas, and E. Vecino, Cannabinoid applications in glaucoma, vol.86, pp.16-23, 2011.

I. Tomida, A. Azuara-blanco, H. House, M. Flint, R. G. Pertwee et al., Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study, J Glaucoma, vol.15, issue.5, pp.349-53, 2006.

M. Karst, K. Salim, S. Burstein, C. I. Hoy, L. Schneider et al., Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial, JAMA, vol.290, issue.13, pp.1757-62, 2003.

S. Steffens, M. Steffens, S. Mach, and F. , Vers un usage thérapeutique de ligands sélectifs du récepteur cannabinoïde 2 dans l'athérosclérose. M/S : médecine sciences, vol.22, pp.7-9, 2006.